Arcturus Therapeutics (ARCT) PT Raised to $79 at Raymond James

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/5/2026

1. HUBS
2. ARM
3. FIS
4. BROS
5. EXPE
6. QCOM
7. CPAY
8. PAYC
9. EW
10. RPD

Go back to Arcturus Therapeutics (ARCT) PT Raised to $79 at Raymond James

Arcturus Therapeutics (ARCT) Begins First Subject Dosing of COVID-19 STARR mRNA Vaccine Candidate, LUNAR-COV19 (ARCT-021) in Phase 1/2 Study

August 11, 2020 8:04 AM EDT

Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) today announced that all subjects in the first cohort have been dosed in the Phase 1/2 clinical study with its ARCT-021 investigational vaccine for COVID-19. The study is being conducted with CTI Clinical Trial and Consulting Services, a global CRO, and in collaboration with Duke-NUS Medical School in Singapore.

We are very pleased to have initiated dosing in our ARCT-021 Phase 1/2 study, and in... More